Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.72 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.72 |
| ▸ | GLA | P06280 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | AHR | P35869 | 1/20 | 0.72 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.72 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.72 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.72 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.72 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.72 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Transtorine SCHEMBL5144405 | 0.84 | KDM4E (1.00) | KDM4EHPGDKMT2ACYP1A2GAA | |
| Transtorine SCHEMBL29366068 | 0.84 | KDM4E (1.00) | KDM4EHPGDKMT2ACYP1A2GAA | |
| Transtorine SCHEMBL29841751 | 0.82 | KDM4E (0.96) | KDM4EHPGDKMT2ACYP1A2GAA | |
| SCHEMBL7738801 | 0.82 | KDM4E (0.72) | KDM4EHPGDKMT2ACYP1A2GAA | |
| Transtorine SCHEMBL30853453 | 0.81 | KDM4E (0.70) | KDM4EHPGDKMT2ACYP1A2GAA | |
| SCHEMBL31243255 | 0.78 | KDM4E (0.66) | KDM4EHPGDKMT2ACYP1A2GAA | |
| SCHEMBL19211217 | 0.78 | HPGD (0.57) | KDM4EHPGDKMT2ACYP1A2GAA | |
| SCHEMBL57291 | 0.78 | KDM4E (0.66) | KDM4EHPGDKMT2ACYP1A2GAA | |
| SCHEMBL13545149 | 0.78 | KDM4E (0.66) | KDM4EHPGDKMT2ACYP1A2GAA | |
| SCHEMBL13543209 | 0.78 | HPGD (0.66) | KDM4EHPGDKMT2ACYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8311066-A | — | — | None | — | — | JP | disclosed |
| US-11058676-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11058676-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3414229-B1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3414229-B1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-10588900-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10588900-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190046520-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20190046520-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2019-02-14 | — | — | US | disclosed |
| EP-3414229-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139274-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139274-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| EP-2201010-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2013-11-06 | — | — | EP | disclosed |
| WO-2012001438-A1 | USE OF KYNURENIC ACID AMIDE DERIVATIVES FOR THE TREATMENT OF HUNTINGTON'S DISEASE | Szegedi Tudományegyetem (HU) | 2012-01-05 | — | — | WO | disclosed |
| WO-2010128345-A1 | KYNURENIC ACID ANALOGUES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE OF SAID COMPOUNDS FOR THE TREATMENT OF HEADACHE | Szegedi Tudományegyetem (HU) | 2010-11-11 | — | — | WO | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1478624-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003068743-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
| JP-H08311066-A | NEW 4-OXOQUINOLINECARBOXAMIDE DERIVATIVE OR ITS SALT | YAMANOUCHI PHARMACEUT CO LTD | 1996-11-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | KDM4E 1685/4885HPGD 1414/4885KMT2A 2114/4885 |
| US-11058676-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | KDM4E 1510/4885HPGD 241/4885KMT2A 796/4885 |
| US-20190046520-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | KDM4E 1510/4885HPGD 241/4885KMT2A 796/4885 |
| US-10588900-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | KDM4E 1510/4885HPGD 241/4885KMT2A 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.